Leap Therapeutics, Inc.
If you purchased Leap Therapeutics, Inc. securities and would like to join the action, please click "Join This Action" below.
LPTX STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE MERGER OF LEAP THERAPEUTICS, INC. IS FAIR TO SHAREHOLDERS
January 24, 2023.
New York, New York—Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Leap Therapeutics, Inc. (NASDAQ: LPTX) and Flame Biosciences, Inc. is fair to Leap shareholders. Under the terms of the merger agreement, Leap will issue approximately 19,794,373 shares of its common stock and approximately 136,833 shares of a newly designated Series X non-voting convertible preferred stock to Flame stockholders.
The investigation concerns whether Leap and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Leap shareholders; and (2) disclose all material information necessary for Leap shareholders to adequately assess and value the merger consideration. On behalf of Leap shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.